Gina Caso
Internal Medicine · Freeport, NYNPI 1720076060
Payments from drug & device makers
Across 66 payments — averaging $18.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$220
- Novo Nordisk$172
- Pfizer$157
- Amarin Pharma, Inc.$115
- Boehringer Ingelheim$100
- Merck$81
- plus $390 from 14 others
What the payments were for
- Food & beverage$1,234100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 11 | $220 |
| Novo Nordisk | 10 | $172 |
| Pfizer | 8 | $157 |
| Amarin Pharma, Inc. | 5 | $115 |
| Boehringer Ingelheim | 5 | $100 |
| Merck | 5 | $81 |
| Sunovion Pharmaceuticals Inc. | 4 | $47 |
| E.r. Squibb & Sons, L.L.C. | 3 | $43 |
| Dermira, Inc. | 1 | $38 |
| Scilex Pharmaceuticals Inc. | 2 | $35 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $34 |
| Amgen | 1 | $32 |
| Bayer | 1 | $30 |
| Endo Pharmaceuticals Inc. | 2 | $26 |
| Daiichi Sankyo Inc. | 1 | $23 |
| Sanofi-aventis U.S. LLC | 1 | $22 |
| Currax Pharmaceuticals LLC | 1 | $17 |
| Dexcom, Inc. | 1 | $15 |
| GSK | 1 | $14 |
| Lilly USA, LLC | 1 | $13 |
How this compares
$1,234 in reported general payments places this provider in the 75th percentile of 9,771 internal medicine providers in New York.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 17 | $16,110 |
| XareltoRivaroxaban | 12 | $9,333 |
| SynthroidLevothyroxine Sodium | 27 | $3,439 |
| Nebivolol Hcl | 12 | $1,070 |
| Levothyroxine Sodium | 49 | $950 |
| Metoprolol Succinate | 45 | $726 |
| Atorvastatin Calcium | 63 | $663 |
| Rosuvastatin Calcium | 49 | $592 |
| Losartan Potassium | 52 | $571 |
| Pantoprazole Sodium | 43 | $519 |
| Simvastatin | 51 | $451 |
| Ezetimibe | 16 | $429 |
| Famotidine | 36 | $424 |
| Omeprazole | 23 | $421 |
| Duloxetine Hcl | 19 | $325 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $157 | $16,11017 claims |
| AbbVieSynthroid | $220 | $3,43927 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 9,771 internal medicine providers in New York.
Other internal medicine in Freeport
- Helena YuNew York$50.9M
- Neha KordeNew York$21.2M
- Karen AutioNew York$18.5M
- Ingo MellinghoffNew York$16.1M
- Gopakumar IyerNew York$12.4M
- David DoveEast Hampton$12.3M
- Robert CupeloEast Syracuse$10.6M
- Patrick ReaganRochester$9.4M
- Sally LauNew York$8.4M
- Angela BrancheRochester$7.9M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.